| Abstrakt: |
A new report discusses research findings on Parkinson's disease, a neurodegenerative disorder characterized by movement impairments and non-motor symptoms. The study focuses on the cannabinoid type-2 receptor (CB2 receptor), which has been studied as a potential target for anti-inflammatory treatment in neurodegenerative diseases. The CB2 receptor is reported to modulate various processes that contribute to neuronal cell death, such as mitochondrial function, oxidative stress, and neuroinflammation. The review summarizes the mechanisms underlying Parkinson's disease pathogenesis and explores the potential regulatory role of the CB2 receptor in the disease. [Extracted from the article] |
